RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
October 14, 2025 at 7:58 PM
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
A review of #machinelearning models developed to support the management of chronic #lymphocyticLeukemia have demonstrated positive outcomes, including accurate diagnosis and improved work flow.
https://bit.ly/3HQxIqV
#lymsm #leusm
https://bit.ly/3HQxIqV
#lymsm #leusm
Machine Learning Models May Improve CLL Diagnosis and Management
Researchers determined machine learning models developed to support the management of CLL have demonstrated positive outcomes.
bit.ly
September 18, 2025 at 7:30 PM
A review of #machinelearning models developed to support the management of chronic #lymphocyticLeukemia have demonstrated positive outcomes, including accurate diagnosis and improved work flow.
https://bit.ly/3HQxIqV
#lymsm #leusm
https://bit.ly/3HQxIqV
#lymsm #leusm
Great work by 2 talented junior investigators. Danny Luan described immune recovery post #CARTcells (paper accepted this week!) & Marina Gomez performed dynamic landmark analysis post CD19 CAR-T #ash24 #lymsm
December 8, 2024 at 2:08 PM
Great work by 2 talented junior investigators. Danny Luan described immune recovery post #CARTcells (paper accepted this week!) & Marina Gomez performed dynamic landmark analysis post CD19 CAR-T #ash24 #lymsm
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Pts w/ Complete Remission B-Cell Lymphoma & Anti-CD20 mAb Therapy: A Case Report of 2 Cases [Apr 14, 2022] Martínez-Chinchilla et al. @FrontImmunol ow.ly/yOSa50IL3mn #COVID19nCancer #lymsm #IDonc #COVID19CP
Frontiers | Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
Immunosuppressant conditions such as hematological malignancies increase the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ...
ow.ly
February 3, 2025 at 12:32 AM
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Pts w/ Complete Remission B-Cell Lymphoma & Anti-CD20 mAb Therapy: A Case Report of 2 Cases [Apr 14, 2022] Martínez-Chinchilla et al. @FrontImmunol ow.ly/yOSa50IL3mn #COVID19nCancer #lymsm #IDonc #COVID19CP
Odronextamab in rare B-NHLs @BachyEmmanuel:
- 46 pts in ELM-2 'other' cohort: HGBL, PMBL, FL3B, BL, EBV+, DHL, THRLBCL
- ORR 61%, CR 44%, 3-yr DOR 54%
- 5 d/c'd d/t TEAEs; 1 G3 CRS, no ICANS; 39% G3 infx, 2 G5 infx
Looking forward to responses by NHL subtype at #ASH24. #lymsm
- 46 pts in ELM-2 'other' cohort: HGBL, PMBL, FL3B, BL, EBV+, DHL, THRLBCL
- ORR 61%, CR 44%, 3-yr DOR 54%
- 5 d/c'd d/t TEAEs; 1 G3 CRS, no ICANS; 39% G3 infx, 2 G5 infx
Looking forward to responses by NHL subtype at #ASH24. #lymsm
November 14, 2024 at 3:42 PM
The @fda.gov Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL #lymsm #oncology
Read more: www.onclive.com/view/fda-app...
Read more: www.onclive.com/view/fda-app...
FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
www.onclive.com
January 17, 2025 at 8:12 PM
The @fda.gov Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL #lymsm #oncology
Read more: www.onclive.com/view/fda-app...
Read more: www.onclive.com/view/fda-app...
December 10, 2024 at 3:22 PM
Poster #ASH24: again, figures speak for themselves. Early ibrutinib in asymptomatic CLL does not improve global QOL and results in worsening of bruising versus placebo. Watch & wait remains the standard of care. #lymsm #leusm #MajorPROsASH
December 7, 2024 at 8:58 PM
Poster #ASH24: again, figures speak for themselves. Early ibrutinib in asymptomatic CLL does not improve global QOL and results in worsening of bruising versus placebo. Watch & wait remains the standard of care. #lymsm #leusm #MajorPROsASH
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
Key Points. Despite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T-cells have poor outcomes.Future tr
ashpublications.org
February 15, 2025 at 5:13 AM
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
🚨 June was a blockbuster month for oncology drug approvals. 🚨
🔐 Sign up to get the full story 📘 on the @US_FDA approvals changing clinical practice: www.onclive.com/view/onclive...
#RegulatoryRundown #oncology #pcsm #lcsm #lymsm #leusm
🔐 Sign up to get the full story 📘 on the @US_FDA approvals changing clinical practice: www.onclive.com/view/onclive...
#RegulatoryRundown #oncology #pcsm #lcsm #lymsm #leusm
July 10, 2025 at 4:11 PM
🚨 June was a blockbuster month for oncology drug approvals. 🚨
🔐 Sign up to get the full story 📘 on the @US_FDA approvals changing clinical practice: www.onclive.com/view/onclive...
#RegulatoryRundown #oncology #pcsm #lcsm #lymsm #leusm
🔐 Sign up to get the full story 📘 on the @US_FDA approvals changing clinical practice: www.onclive.com/view/onclive...
#RegulatoryRundown #oncology #pcsm #lcsm #lymsm #leusm
Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL #EBMT25 #lymsm #oncology www.onclive.com/view/compara...
Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL
Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.
www.onclive.com
April 1, 2025 at 7:40 PM
Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL #EBMT25 #lymsm #oncology www.onclive.com/view/compara...
>1500 trial & @cibmtr.bsky.social pts who received liso-cel:
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML
June 18, 2025 at 6:30 PM
>1500 trial & @cibmtr.bsky.social pts who received liso-cel:
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma
#lymsm #hematology #oncology
www.onclive.com/view/liso-ce...
#lymsm #hematology #oncology
www.onclive.com/view/liso-ce...
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma
Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.
www.onclive.com
February 10, 2025 at 5:39 PM
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma
#lymsm #hematology #oncology
www.onclive.com/view/liso-ce...
#lymsm #hematology #oncology
www.onclive.com/view/liso-ce...
Golcadomide (CELMoD)+RCHOP 1L LBCL @Lymphoma_Doc #ASH24:
- randomized to 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
- randomized to 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
November 18, 2024 at 2:58 PM
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups @ash-hematology.bsky.social #ASH24 #lymsm #oncology
www.onclive.com/view/zuma-2-...
www.onclive.com/view/zuma-2-...
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups
Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.
www.onclive.com
January 6, 2025 at 8:27 PM
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups @ash-hematology.bsky.social #ASH24 #lymsm #oncology
www.onclive.com/view/zuma-2-...
www.onclive.com/view/zuma-2-...
Tabelecleucel R/R EBV+ PTLD #ASH24:
- off-the-shelf EBV allo CTL
- 75 pts, 24% ECOG 2+, all prior R+/-chemo
- ORR 51%, CR 28%, mDOR 23 mo
- 1-yr OS 56% (responders 79%)
- no G5 TEAEs, no CRS/ICANS, GVHD, organ rejection
Important option in pts with otherwise very poor OS. #lymsm
- off-the-shelf EBV allo CTL
- 75 pts, 24% ECOG 2+, all prior R+/-chemo
- ORR 51%, CR 28%, mDOR 23 mo
- 1-yr OS 56% (responders 79%)
- no G5 TEAEs, no CRS/ICANS, GVHD, organ rejection
Important option in pts with otherwise very poor OS. #lymsm
November 26, 2024 at 3:57 PM
Quick #ASH24 quip: 24 pts living with HIV who received axi-cel. mLOT 3. 88% CRS (1 G3), 33% ICANS (3 G3). ORR 50%, CR 42%. 1-yr PFS/OS 40%/55% (comparable to 3L CAR data). Persons living with HIV must be included in CAR trials. #lymsm #celltherapy
November 23, 2024 at 10:38 AM
Quick #ASH24 quip: 24 pts living with HIV who received axi-cel. mLOT 3. 88% CRS (1 G3), 33% ICANS (3 G3). ORR 50%, CR 42%. 1-yr PFS/OS 40%/55% (comparable to 3L CAR data). Persons living with HIV must be included in CAR trials. #lymsm #celltherapy
It's time for the #FiveUnder5 🕙 📹 : The top 5 #OncLiveTV clips of the week, all in one place: www.onclive.com/view/five-un... #lcsm #bcsm #lymsm #mmsm #oncology
February 9, 2025 at 6:43 PM
It's time for the #FiveUnder5 🕙 📹 : The top 5 #OncLiveTV clips of the week, all in one place: www.onclive.com/view/five-un... #lcsm #bcsm #lymsm #mmsm #oncology
Time-limited VIPOR MCL @MelanicjMD #ASH24
- 37 pts, 20 untreated, 34% whole cohort TP53mut
- significant hypokalemia (27% G3!), diarrhea, rash
- CR: 94% R/R, 100% untreated (!!!), 92% TP53mut
- 2-yr TTP 95% 1L, 92% R/R
Great data, especially TP53mut-enriched R/R cohort. #lymsm
- 37 pts, 20 untreated, 34% whole cohort TP53mut
- significant hypokalemia (27% G3!), diarrhea, rash
- CR: 94% R/R, 100% untreated (!!!), 92% TP53mut
- 2-yr TTP 95% 1L, 92% R/R
Great data, especially TP53mut-enriched R/R cohort. #lymsm
December 9, 2024 at 8:05 PM
Every year this is how I feel after ASH. A final #ASHaiku
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Are you feeling revitalized? 🎇
#ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned.
Here's to a fantastic final day in San Diego!☀️ #HemeSky #Hematology
#ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned.
Here's to a fantastic final day in San Diego!☀️ #HemeSky #Hematology
December 10, 2024 at 9:11 PM
Every year this is how I feel after ASH. A final #ASHaiku
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Want to hear about the potential use of multi-virus-specific T-cells to enhance the activity of bispecifics in #lymphoma?🩸
Then check out our interesting interview with Akiva Diamond of @bcmhouston.bsky.social from the recent #ASCO25 meeting:
👉 buff.ly/O2r5EuF
#LYMsm @ascocancer.bsky.social
Then check out our interesting interview with Akiva Diamond of @bcmhouston.bsky.social from the recent #ASCO25 meeting:
👉 buff.ly/O2r5EuF
#LYMsm @ascocancer.bsky.social
June 11, 2025 at 5:02 PM
Want to hear about the potential use of multi-virus-specific T-cells to enhance the activity of bispecifics in #lymphoma?🩸
Then check out our interesting interview with Akiva Diamond of @bcmhouston.bsky.social from the recent #ASCO25 meeting:
👉 buff.ly/O2r5EuF
#LYMsm @ascocancer.bsky.social
Then check out our interesting interview with Akiva Diamond of @bcmhouston.bsky.social from the recent #ASCO25 meeting:
👉 buff.ly/O2r5EuF
#LYMsm @ascocancer.bsky.social